Skip to main content
Clinical Trials/NCT07354347
NCT07354347RecruitingNot Applicable

Optimal ATP Settings in the VT Zone for New Implantable Cardioverter Defibrillator (ICD) Implantation (DAN-ATP)

Rigshospitalet, Denmark2 sites in 1 country3,980 target enrollmentStarted: February 1, 2026Last updated:
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
3,980
Locations
2
Primary Endpoint
Arrhythmia cessation

Study Overview

Brief Summary

This is a pragmatic, two-group, cluster randomized trial designed to compare strategies for the Anti Tachycardia Pacing (ATP)-setting in the ventricular tachyarrhythmias (VT) zone when implanting a new implantable cardioverter defibrillator (ICD) in patients with heart disease in hospitals in Denmark.

The strategies are: "Burst" or "Ramp" after 1. ATP (which is always burst) in VT zone. VT zone is defined between 180-249 (up to 269 in special cases) heartbeats per minute.

The ICD will give either:

Burst: The ICD is programmed to give ATP with 4 bursts. Or Ramp: The ICD is programmed to give ATP with 1 burst and 3 ramps.

The participating hospitals will be assigned to one of two intervention strategies for periods of 4-months. The given intervention will follow the patient/ICD throughout the life time of the ICD, but with the possibility to reprogram at any time (intention to treat).

It is calculated that the study needs a total of 398 events (second to fourth ATP), which is estimated to require 3980 implanted ICDs. The participants will be followed until the end of the ICD life, which is estimated to be around 10 years.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • - ICD implantation for primary or secondary prophylactic indication

Exclusion Criteria

  • Patients can actively opt out of participation in the study

Arms & Interventions

Burst

Experimental

Intervention: Burst (Other)

Ramp

Experimental

Intervention: Ramp (Other)

Outcomes

Primary Outcomes

Arrhythmia cessation

Time Frame: The lifetime of the ICD, estimated 10 years

The ability of the given ATP protocol to stop the ventricular arrhythmia

Secondary Outcomes

  • Defibrillation(The lifetime of the ICD, estimated 10 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Bo Gregers Winkel

Chief Physician

Rigshospitalet, Denmark

Study Sites (2)

Loading locations...

Similar Trials